Also trades as: CYTHW (NASDAQ) · $vol 0M
CYTH NASDAQ
Cyclo Therapeutics, Inc.
1W: +6.0%
1M: -6.3%
3M: +19.7%
1Y: -49.6%
3Y: -75.7%
5Y: -96.0%
$0.72
Last traded 2025-03-27 — delisted
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
No convergence signal
Key Statistics
Market Cap$23.6M
52W Range0.55-1.6199
Volume186,806
Avg Volume1,864,521
Beta-0.57
Dividend—
Analyst Ratings
Company Info
CEON. Scott Fine
Employees8
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
IPO Date2000-05-03
Websitecyclotherapeutics.com
6714 NW 16th Street
Gainesville, FL 32653
US
Gainesville, FL 32653
US
386 418 8060
About Cyclo Therapeutics, Inc.
Cyclo Therapeutics, Inc., a clinical stage biotechnology company, develops cyclodextrin-based products for the treatment of various diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug, which is Phase III clinical trials for the treatment of Niemann-Pick Type C disease. The company also develops Trappsol Cyclo for the treatment of Alzheimer's disease. In addition, it sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo Therapeutics, Inc. in September 2019. Cyclo Therapeutics, Inc. was incorporated in 1990 and is based in Gainesville, Florida.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| CONKLING WILLIAM | A-Award | 27,654 | — | 2025-02-27 |
| Wong Vivien | A-Award | 25,140 | — | 2025-02-27 |
| Cross Shawn | A-Award | 28,597 | — | 2025-02-27 |
| Toig Randall M. | A-Award | 33,311 | — | 2025-02-27 |
| STRATTAN CE RICK | A-Award | 30,169 | — | 2025-02-27 |